Study of TST005 in Patients With Locally Advanced or Metastatic Solid Tumors

Summary

This is an open label Phase 1, first-in-human (FIH) study of TST005, a bi-specific antibody consisting of a PD-L1 monoclonal antibody (mAb) and a transforming growth factor beta (TGF-β) trap in subjects with locally advanced or metastatic cancers

Timeline

Start

2021-06-11

Primary completion

2023-09-30

Completion

2023-09-30

Outcome

Outcome not reported

Stopped: “Corporate Decision”

Drugs

Indications